



**NATIONAL CANCER INSTITUTE**

**Grant Number:** 5R37CA219697-02  
**FAIN:** R37CA219697

**Principal Investigator(s):**  
Kian H Lim, MD

**Project Title:** IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma

TERI MEDLEY  
Washington University  
1 Brookings Drive  
Campus Box 8018  
St. Louis, MO 631304862

**Award e-mailed to:** researchgrants@wusm.wustl.edu

**Period Of Performance:**

**Budget Period:** 02/01/2019 – 01/31/2020

**Project Period:** 02/08/2018 – 01/31/2023

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$338,378 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to WASHINGTON UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R37CA219697. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Alice Chi Wong  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows

**American Cancer Society  
Research Scholar Grant  
(RSGHP, RSGI, RSGM, RSGPB, RSGT)  
Activation Form**



Principal Investigator: Kian-Huat, Lim	
Institution: Washington University School of Medicine	
Grant Number: RSG-17-203-01-TBG	Grant Application Date: 04/03/2017
Award Period: 01/01/2018-12/31/2021	Approved Budget: \$660,000
Title of Project: IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC CANCER	
IRB Approval Required? Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> Date Approved: _____	IACUC Approval Required? Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Date Approved: <u>07/22/2016</u>

- The Principal Investigator must sign this form indicating that s/he has accepted the above indicated grant and received a copy of the Society's grant policy statement. The grantee institution's business officer or other official authorized to sign for the institution must also sign this form.
- It is understood that the Principal Investigator and the grantee institution, by the act of accepting this American Cancer Society grant, agree to abide by the Society's RESEARCH SCHOLAR GRANT POLICIES effective January 2017 (enclosed) including the Society's patent policy and a failure to comply with such Policies or with any other terms in connection with the grant may result in the American Cancer Society suspending or cancelling grant funding, to be decided by the American Cancer Society in its sole discretion.
- Upload completed and signed form into Post Award Management System. For submitting IRB and IACUC approval letters please see Post Award Management System Instructions for Downloading and Uploading Deliverable (enclosed in Award Packets).
- No funds will be disbursed to the institution until this activation form is received by the Society.

**REQUIRED SIGNATURES**

NAME OF PRINCIPAL INVESTIGATOR (please print): K	TITLE:
SIGNATURE: 	DATE:
NAME OF INSTITUTION OFFICIAL (please print):	TITLE:
SIGNATURE:	DATE:

Address of institution office to which checks should be mailed (to be completed by institution's business officer). The American Cancer Society requires that all grant payments be made to the grantee's sponsoring institution, and be mailed to that institution.

.....  
Checks payable to: Sponsored Projects Accounting

Attention of (office): Joseph M Gindhard

Building/Room No. Campus Box 1034

Street Address 700 Rosedale Ave

City, State, Zip St. Louis, MO, 63112-1408

Phone number:

**Please Note: If this grant is not accepted, the institution and/or principal investigator must submit the Request for Cancellation form as indicated in the RESEARCH SCHOLAR GRANT POLICIES.**

## Siteman Investment Program (SIP) Notice of Award

Grantor Institution Names: ☐ The Foundation for Barnes Jewish Hospital ☒ Siteman Cancer Center  
☒ *This Notice of Award is for partial funding of a joint award from The Foundation for Barnes-Jewish Hospital and Siteman Cancer Center.*  
☐ *This Notice of Award fully funds your SIP award.*

Grantee Institution: Washington University

Principal Investigator: Kian Lim, MD, PhD

Project Title: Development of Novel ERK Inhibitor-Based Therapeutic Combinations In Pancreatic Cancer Based On Proteo-Transcriptomic Analyses

Mechanism: Pre-R01

Grant Reference: N/A

Project Period: 1/1/2020 to 12/31/2021

Project Funding: \$40,000 directs over 2 years

Year 1 Progress Report Due: 30 days prior to budget period end date

Year 2 Progress Report Due: 60 days after grant end date

Abbreviated Progress Reports Due: Annually following the grant end date for three years

### 1<sup>st</sup> Year Approved Budget:

Personnel:	
Supplies:	24,000
Other Expenses:	
Direct Costs:	24,000
Indirect Costs:	0
Total Costs for Year 1:	24,000

### 2<sup>nd</sup> Year Approved Budget:

Personnel:	
Supplies:	16,000
Other Expenses:	
Direct Costs:	16,000
Indirect Costs:	0
Total Costs for Year 2:	16,000

Items deleted from the original budget by the Review Committee: N/A

### Reporting Requirements:

Year 1 progress report is due 30 days prior to the budget period end date of first year of funding. Year 2 funds will be released upon receipt of progress report. Year 2 progress report is due 60 days after the project end date. An abbreviated progress report will be due annually for three years following the end of this award/grant.

Progress Report guidelines and form will be provided for coordination with required Siteman Cancer Center reporting. Future disbursements may be affected if grant recipient is delinquent in submitting their comprehensive progress report by the due date listed above.

**Pre-SPORE/PPG Awards:** All pre-SPORE/PPG projects must present on the scientific progress to Siteman Cancer Center Senior Leadership in the last quarter of year 1 of their award. If scientific progress is not demonstrated, or if there are other apparent issues affecting the project, Senior Leadership may reduce or withhold year 2 funds. During year 1, it is expected that the PI will take steps to advance towards a submission (e.g. meet with NIH/NCI, formulate a timeline, establish an IAB/EAB, etc.).

### **Terms & Conditions:**

This grant/award is based on the request for funding approved by Siteman Cancer Center (SCC) after competitive review of applications submitted to the Siteman Investment Program. Funds for the aforementioned request will be allocated from SCC and/or The Foundation for Barnes-Jewish Hospital. Failure to comply with the terms and conditions in this Notice of Award may result in denial of future funding.

### **Allowable & Unallowable Expenses:**

Award recipients will follow institutional policies/guidelines. Based on the terms of the award, the Grantor expects expenditures to be within budget, reasonable and in accordance with Grantee Institutional policy. The following are guidelines for frequently questioned expenditures that are allowable and unallowable unless specifically approved by the Foundation for Barnes-Jewish Hospital and Siteman Cancer Center.

<b><i>Allowable Expenses</i></b>	<b><i>Unallowable Expenses</i></b>
<ul style="list-style-type: none"> <li>▪ Salary support for investigators and other relevant faculty collaborators or staff. The NIH salary cap should be used in the budget</li> <li>▪ Per diem charges for patients, if part of the clinical study, not reimbursable by standard payment terms</li> <li>▪ Stipends for graduate students and postdoctoral assistants if their role is to promote and sustain the project presented by the faculty member</li> <li>▪ Domestic and foreign travel when necessary to carry out the proposed research project based on the Grantee's institutional travel policy</li> <li>▪ Publication costs not to exceed \$2,000 across the total project period</li> <li>▪ Consultant costs</li> <li>▪ Equipment/technology purchased with the intent to design, test or facilitate a new device and non-office equipment necessary to carry out the proposed award/grant. Equipment requests over \$5,000 must be accompanied with a detailed justification</li> </ul>	<ul style="list-style-type: none"> <li>▪ Secretarial/administrative personnel salary support</li> <li>▪ Office equipment and supplies</li> <li>▪ Computer/equipment maintenance fees</li> <li>▪ Tuition</li> <li>▪ Travel and/or registration/related fees for conferences. Any travel not essential to carrying out the proposed research</li> <li>▪ Purchasing and binding of periodicals and books</li> <li>▪ Dues and membership fees in scientific societies</li> <li>▪ Honoraria and travel expenses for visiting lecturers</li> <li>▪ Recruiting and relocation expenses</li> <li>▪ Administrative or institutional charges for services normally considered overhead (e.g. space rental, utilities, etc.)</li> <li>▪ Non-medical or personnel services to patients</li> <li>▪ Construction or building maintenance</li> <li>▪ Sub-contracts to institutions not affiliated with Siteman Cancer Center</li> <li>▪ Pre-award costs</li> </ul>

### **Payment of Grant:**

Payment of funding from The Foundation for Barnes-Jewish Hospital is on a cost reimbursement basis. Quarterly invoices summarized by direct and indirect cost line items should be directed to The Foundation for Barnes-Jewish Hospital, Donald Buckner, Grants and Funds Administration Manager, 1001 Highlands Plaza Drive West, Suite 140, St. Louis, MO 63110. Invoices should reference aforementioned grant reference number. A final invoice must be submitted within 60 days of the grant expiration date.

**For WU Recipients:** Payment of funding from the Siteman Cancer Center will be made by a project period basis through fund allocations set-up within the PI and/or co-PI's department. All unspent funds at the end of the grant period will be returned to Siteman Cancer Center.

**For SLU Recipients:** Payment of funding from Siteman Cancer Center is on a cost reimbursement basis. Quarterly invoices summarized by direct and indirect cost line items should be directed to the Siteman Cancer Center contact listed below. Invoices should reference the PI and grant/award title. A final invoice must be submitted within 60 days of the grant expiration date.

**Subsequent Funding & Publications:**

The Siteman Investment Program is designed to award pilot funding to faculty to support pioneering cancer research and produce data to leverage further external peer-reviewed funding. Subsequent cancer-related grants (return on investment) and publications are tracked through progress report submissions and are a significant component in leveraging the success of a SIP project. SIP recipients are expected to work towards securing peer-reviewed, cancer-related funding (ideally from the NCI) and to publish findings in cancer-focused journals.

The appropriate funding source must be acknowledged in any publication resulting from this grant. Copies of all abstracts and reprints acknowledging the appropriate funding sources (checked below) should be directed to Donald Buckner at The Foundation for Barnes-Jewish Hospital and Jaclyn McGuire at Siteman Cancer Center, [Donald.Buckner@bjc.org](mailto:Donald.Buckner@bjc.org) and [mcguirej@wustl.edu](mailto:mcguirej@wustl.edu).

- ☒ **Alvin J. Siteman Cancer Center, Siteman Investment Program**
- ☒ **The Foundation for Barnes-Jewish Hospital, Cancer Frontier Fund**
- ☐ **National Cancer Institute, Cancer Center Support Grant, P30 CA091842**
- ☐ **Fashion Footwear Charitable Foundation of New York, Inc.**
- ☒ **Barnard Trust**
- ☐ **Siteman Cancer Center Discovery Fund**

**Example acknowledgement statement:** *This research was supported by the Alvin J. Siteman Cancer Center Siteman Investment Program (supported by [list sources of support checked above]).*

**Donor Relations:**

The Siteman Investment Program is supported through various donors and organizations as listed above. Siteman Cancer Center relies on SIP awardees to respond as needed to donor relations' requests including, but not limited to: speaking engagements or participation at donor-sponsored events, media interviews, or lab tours and discussion of your research. In accepting this award, the PI understands the importance and agrees to participate and respond to donor relations' requests.

In addition, SIP awardees, and their labs, are expected to participate in Pedal the Cause annually. Pedal the Cause donates 100% of funds raised to Siteman Cancer Center & St. Louis Children's Hospital for cancer research, the majority of which supports the Siteman Investment Program. There are many ways to participate in Pedal the Cause, including as a rider, virtual rider, or volunteer.

**Rebudgeting:**

Rebudgeting is allowed within the approved categories if it meets the purpose of completing the project. Funds may not be rebudgeted for items deleted from the original budget (see page 1). Any rebudgeting that changes a budget category by 25% or greater must be approved by The Foundation for Barnes-Jewish Hospital and Siteman Cancer Center. Requests should be directed to the contacts lists below.

**Carryover – Multi-Year Projects:**

Carryover of an unobligated balance into the next budget period will be automatic for projects with an acceptable progress report.

**Carryover – Single-Year Projects:**

Carryover of an unobligated balance is not applicable for Single Year Project Awards.

**No Cost Extensions:**

Request for extensions must be submitted two (2) weeks prior to the grant expiration date. Extensions may be granted for up to one year if needed to complete the work. Requests should be directed to the Foundation for Barnes-Jewish Hospital and Siteman Cancer Center (contact information listed below).

**Change in Grantee or Grantee Institution:**

Changes in the Grantee must be approved in advance by the Grantee's institutional official, Siteman Cancer Center and The Foundation for Barnes-Jewish Hospital. No changes in Grantee Institution will be allowed.

**Change in Percent in Effort:**

Grantees are required to devote adequate effort to complete the project. Any change to the original commitment of effort for key personnel must be approved by the Grantee's institutional official, Siteman Cancer Center and The Foundation for Barnes-Jewish Hospital.

**Change in Scope:**

Any change in the direction, type of research or program/activity, or other areas that constitutes a significant change from the aims, objectives, or purposes of the approved project must be approved in advance by the Grantee's institutional official, Siteman Cancer Center and the Siteman Investment Program review chair, and The Foundation for Barnes-Jewish Hospital. Requests should be directed to the Foundation for Barnes-Jewish Hospital and Siteman Cancer Center (contact information listed below).

**Human Subjects and/or Laboratory Animals:**

If the funds for this award are used to support research that requires an IRB and/or IACUC protocol, it is understood that the award for research meets compliance requirements and that proper approvals will be on file at the Grantee Institution. The Grantee Institution further agrees to provide proper approvals to Siteman Cancer Center prior to funds being allocated.

**Intellectual Property:**

At such time that a discovery or invention is made with the support, in whole or in part, from this grant, The Foundation for Barnes-Jewish Hospital and Washington University will negotiate mutually acceptable terms. Discoveries or inventions must be reported to The Foundation for Barnes-Jewish Hospital.

**Audit:**

The Foundation for Barnes-Jewish Hospital and Siteman Cancer Center reserve the right to audit Grantee Institution's financial records and compliance performance pertaining to this award/grant.

**Contacts:**

Donald Buckner, Grants and Funds Administration Manager  
1001 Highlands Plaza Drive West, Suite 140, St. Louis, MO 63110  
Phone: (314) 286-0349  
Email: [Donald.Buckner@bjc.org](mailto:Donald.Buckner@bjc.org)

Jaclyn McGuire, Senior Grant Specialist  
Siteman Cancer Center  
4901 Forest Park Avenue, Campus Box 8100, St. Louis, MO 63108  
Phone: (314) 454-8439  
Email: [mcguirej@wustl.edu](mailto:mcguirej@wustl.edu)

## Lim, Kian-Huat

---

**From:** Grierson, Patrick  
**Sent:** Tuesday, March 9, 2021 2:43 PM  
**To:** Lim, Kian-Huat  
**Subject:** Fw: Emerson Collective Cancer Research Fund: Application Notification

---

**From:** Katherine Szarama <pcsupport@altum.com>  
**Sent:** Monday, March 30, 2020 4:55 AM  
**To:** Grierson, Patrick <grierson@wustl.edu>  
**Subject:** Emerson Collective Cancer Research Fund: Application Notification

Hello,

Thank you for your application to the Emerson Collective Cancer Research Fund. We received a large number of outstanding proposals and are very pleased to inform you that your proposal was selected for award.

To officially kickoff your award, visit <https://proposalcentral.com> to accept the terms and complete any award acceptance deliverable by **Friday 10 April 2020**. We here at the Emerson Collective are proud to support innovative cancer research and see our partnership as a long-term commitment. We wish you congratulations on your selection and success with your research endeavors.

Sincerely,

Katherine B. Szarama, PhD  
Manager, Research and Venture Grants, Health

Reed Jobs,  
Managing Director, Health  
**Emerson Collective**  
[www.emersoncollective.com/health](http://www.emersoncollective.com/health)